{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:32:17Z","timestamp":1774488737949,"version":"3.50.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Vitiligo is the most common depigmentation disorder, affecting around 1% of the population worldwide. Currently, no national or international registry for patients with vitiligo exists. Individual dermatologists maintain descriptive databases of such patients, which involve patients in one centre. However, such single-centre registries do not aim to establish the short- and long-term safety (pharmacovigilance) and effectiveness of vitiligo therapies. As an initial step for the development of a national UK registry for patients with vitiligo, development of a pilot multicentre registry in the UK is needed. This pilot study is being developed in collaboration with the British Association of Dermatologists. VIRTUAL-UK (VItiligo RegisTry for adUlts And chiLdren) assesses treatment effectiveness and safety as well as treatment impact on quality of life. The registry includes children and adults with vitiligo who receive phototherapy or novel topical and\/or systemic immunomodulatory therapies. The VIRTUAL-UK registry will ultimately (i) inform treatment guidelines, (ii) provide pharmacogenetic and pharmacodynamic research data, (iii) help answer questions on skin cancer risk for patients with vitiligo who receive prolonged phototherapy courses, especially regarding high cumulative exposures in children with less deeply pigmented skin, and (iv) help to identify those patients likely to experience rapid disease progression. As a result, this registry will ultimately improve and personalize patient care. With novel topical and oral immunomodulatory therapies having just entered vitiligo clinical practice, the timing is ideal to harness the high-quality data collection offered by the UK National Health Service.<\/jats:p>","DOI":"10.1093\/ced\/llaf249","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T09:02:34Z","timestamp":1751014954000},"page":"1982-1988","source":"Crossref","is-referenced-by-count":1,"title":["Multicentre, prospective, observational clinical registry of paediatric and adult patients with vitiligo on phototherapy, or novel topical or systemic immunomodulatory therapies"],"prefix":"10.1093","volume":"50","author":[{"given":"Viktoria","family":"Eleftheriadou","sequence":"first","affiliation":[{"name":"Dermatology, Royal Wolverhampton NHS Trust , Wolverhampton ,","place":["UK"]},{"name":"Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham , Birmingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Rush","sequence":"additional","affiliation":[{"name":"Vitiligo Support UK , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine","family":"Jacques","sequence":"additional","affiliation":[{"name":"Research and Development Directorate, Royal Wolverhampton NHS Trust , Wolverhampton ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"2025092509024970900_llaf249-B1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"2025092509024970900_llaf249-B2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bjd.20596","article-title":"British Association of Dermatologists guidelines for the management of people with vitiligo 2021","volume":"186","author":"Eleftheriadou","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025092509024970900_llaf249-B3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/gm199","article-title":"The genetics of generalized vitiligo: autoimmune pathways and an inverse relationship with malignant melanoma","volume":"2","author":"Spritz","year":"2010","journal-title":"Genome Med"},{"key":"2025092509024970900_llaf249-B4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/bjd.16703","article-title":"Risk of skin cancer in people with vitiligo: a systematic review and meta-analysis","volume":"179","author":"Ban","year":"2018","journal-title":"Br J Dermatol"},{"issue":"Suppl. 1","key":"2025092509024970900_llaf249-B5","first-page":"212","article-title":"PD01: the VOICE registry: a vitiligo database \u2013 our first year","volume":"187","author":"Mathew","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025092509024970900_llaf249-B6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/pcmr.12354","article-title":"Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus","volume":"28","author":"Eleftheriadou","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"2025092509024970900_llaf249-B7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bjd.17013","article-title":"International Initiative for Outcomes (INFO) for vitiligo: workshops with vitiligo patients on repigmentation","volume":"180","author":"Eleftheriadou","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025092509024970900_llaf249-B8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jaad.2021.06.880","article-title":"Development and validation of the fingertip unit for assessing Facial Vitiligo Area Scoring Index","volume":"86","author":"Bae","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025092509024970900_llaf249-B9","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jid.2015.12.040","article-title":"Development and validation of the Vitiligo Extent Score (VES): an international collaborative initiative","volume":"136","author":"van Geel","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2025092509024970900_llaf249-B10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjd.14208","article-title":"Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success","volume":"174","author":"Batchelor","year":"2016","journal-title":"Br J Dermatol"},{"key":"2025092509024970900_llaf249-B11"},{"key":"2025092509024970900_llaf249-B12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/JID.2015.398","article-title":"The Vitiligo Impact Patient Scale (VIPs): development and validation of a vitiligo burden assessment tool","volume":"136","author":"Salzes","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2025092509024970900_llaf249-B13","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"2025092509024970900_llaf249-B14","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"key":"2025092509024970900_llaf249-B15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/jdv.17742","article-title":"Vitiligo Treatment Impact score (VITs): development and validation of a vitiligo burden of treatment questionnaire using the ComPaRe Vitiligo e-cohort","volume":"36","author":"Shourick","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025092509024970900_llaf249-B16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/bjd\/ljad331","article-title":"Roadmap to VIRTUAL-GLOBAL: coordinating VItiligo RegisTries for adUlts And chiLdren internationally","volume":"190","author":"Eleftheriadou","year":"2023","journal-title":"Br J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf249\/63510733\/llaf249.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/10\/1982\/63510733\/llaf249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/10\/1982\/63510733\/llaf249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:02:57Z","timestamp":1758805377000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/10\/1982\/8165982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":16,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,6,17]]},"published-print":{"date-parts":[[2025,9,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf249","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,6,17]]}}}